跳至主要内容
临床试验/EUCTR2020-002850-26-NL
EUCTR2020-002850-26-NL进行中(未招募)1 期

Vaccination response to pneumococcal antigen as novel predictor for successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: the vaccinSTOP study. - VaccinSTOP study

Albert Schweitzer Hospital0 个研究点目标入组 57 人开始时间: 2020年6月30日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
57

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Aged 18 years or older
  • -Written informed consent
  • -Known baseline data on diagnosis and treatment prior to study entry
  • -Eligible for TKI discontinuation according to current HOVON guidelines on the treatment of CML
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 27

排除标准

  • -Previously vaccinated against S. pneumoniae
  • -Known allergy to any constituent of the pneumococcal vaccine
  • -Patients using any immunosuppressive medication, excluding inhalation corticosteroids and ointments containing corticosteroids

研究者

相似试验